Loading...
01/11 16:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative factors: a significant revenue decline in U.S. Generics, currency and tariff headwinds, and an enVista recall impacting revenue and EBITDA. Although there is revenue growth in Vision Care and Surgical segments, the overall financial health is weakened by an adjusted EPS loss and lack of a shareholder return plan. The Q&A section indicates cautious optimism but highlights uncertainties in tariff impacts and unclear management responses. These factors suggest a negative market reaction, likely resulting in a stock price decrease of -2% to -8% over the next two weeks.
Total Revenue $1.137 billion, reflecting growth of 5% year-over-year. This growth was driven by strong performance in the Vision Care and Surgical segments.
Vision Care Revenue $656 million, increased by 5% year-over-year, fueled by growth in both consumer and contact lenses.
Surgical Revenue $214 million, an increase of 11% year-over-year, driven by premium IOLs and solid growth across all product categories.
Pharmaceutical Revenue $267 million, representing growth of 1% year-over-year, with mixed performance across the segment.
Adjusted Gross Margin 59.5%, impacted by a one-time headwind of approximately 140 basis points related to the enVista recall.
Adjusted EBITDA $126 million, which includes a one-time impact of $16 million related to inventory write-off due to the enVista recall.
Net Interest Expense $91 million for the quarter.
Adjusted EPS Loss of $0.07 for the quarter.
MIEBO Revenue $57 million, representing year-over-year growth of over 100%.
XIIDRA Revenue $67 million, with growth dynamics impacted by higher gross to net deductions.
U.S. Generics Revenue Declined by 23% year-over-year due to increased competition and lower inventory.
CapEx Expected to be approximately $280 million for the full year.
Adjusted EBITDA Guidance Updated to a range of $850 million to $900 million, absorbing the one-time impact related to the enVista recall.
Revenue Guidance Updated to a range of $5 billion to $5.1 billion, absorbing an estimated $55 million one-time impact of the enVista recall.
New Product Launches: Blink NutriTears, a clinically-proven OTC nutritional supplement for dry eyes, launched in the U.S. with a 10x increase in sales at major retailers. March launch of Arise, a lens-fitting system using cloud-based technology for OrthoK lens design. Expected introduction of multifocal and toric options for Daily SiHy contact lenses in 2026. Pending launch of LuxLife IOLs in Europe by the end of Q2 2025. Anticipated soft launch of enVista Envy in Europe later this year.
Market Expansion: Daily SiHy contact lenses saw 42% constant currency revenue growth in Q1, with 56% growth in the U.S. Plans to introduce Daily SiHy toric option in Japan, the second largest market for contact lenses. International Pharma business grew by 6% in Q1, with strong performance in Europe.
Operational Efficiencies: Enhanced inspection protocols for IOLs and established explicit standards for vendors post-recall. Optimizing global manufacturing presence to mitigate tariff impacts.
Strategic Shifts: Focus on long-term profitable growth and reestablishing Bausch + Lomb as the best eye health company. Addressing U.S. Generics underperformance and XIIDRA revenue headwinds.
Recall of IOLs: The voluntary recall of intraocular lenses (IOLs) on the enVista platform due to a toxic anterior segment syndrome (TASS) signal detected in certain lenses, which could impact revenue and market trust.
Tariff Environment: The evolving tariff landscape, particularly the exposure from exporting to China, poses a risk to profitability. The company is exploring various strategies to mitigate the impact, including inventory stocking and reevaluating pricing.
U.S. Generics Business: The U.S. Generics segment faced increased competition and lower inventory levels, resulting in a significant decline of 23% in revenue, which could affect overall financial performance.
XIIDRA Revenue Headwinds: XIIDRA experienced gross to net adjustments due to the Inflation Reduction Act, impacting revenue despite an increase in prescriptions.
Currency Headwinds: Currency fluctuations presented a headwind of approximately $19 million to revenue and $7 million to adjusted EBITDA, affecting financial results.
Impact of enVista Recall: The enVista recall is expected to have a one-time impact of approximately $55 million to revenue and $65 million to adjusted EBITDA for the year.
Tariff Impact on EBITDA: Estimated potential headwind of approximately 120 basis points to adjusted EBITDA margin in 2025 due to tariffs, which is not fully reflected in current guidance.
Core Strategy: Reestablish Bausch + Lomb as the best eye health company with a focus on long-term profitable growth.
Innovation Pipeline: Enthusiasm around the innovation pipeline is high, with several products expected to enhance the standard of care in eye health.
Market Response to Recall: Successfully managed the voluntary recall of enVista IOLs, returning to market within a month and enhancing inspection protocols.
Growth Drivers: MIEBO prescriptions grew 98% year-over-year, with significant growth in the Blink product line and Daily SiHy contact lenses.
Tariff Mitigation: Evaluating multiple levers to mitigate potential tariff impacts, including inventory stocking and manufacturing adjustments.
2025 Revenue Guidance: Updated revenue guidance raised to $5 billion to $5.1 billion, absorbing a $55 million impact from the enVista recall.
2025 Adjusted EBITDA Guidance: Updated adjusted EBITDA guidance to a range of $850 million to $900 million, absorbing a $65 million impact from the enVista recall.
Adjusted Gross Margin: Expected to be approximately 61.5%, absorbing a 60 basis point headwind from the enVista recall.
CapEx Guidance: Full year CapEx expected to be approximately $280 million.
Tax Rate Guidance: Adjusted tax rate expected to be approximately 15%, at the low end of previous guidance.
Shareholder Return Plan: Bausch + Lomb Corporation has not announced any specific share buyback program or dividend program during the Q1 2025 earnings call.
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
The earnings call highlights strong growth in key areas like MIEBO and contact lenses, despite challenges in the generics sector. Raised guidance for 2025 and successful recall management indicate resilience. The Q&A session reinforces confidence with strategic plans and market opportunities, despite some guidance ambiguities. Overall, positive developments in innovation, market strategy, and shareholder returns suggest a favorable stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
